An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo

Hin Chu(HKU-Pasteur Research Pole), Shengyong Yang(Sichuan University), Hoi Ting Wong(University of Hong Kong), Ziyi Xia(Sichuan University), Xiaoyan Xia(Guangzhou Women and Children Medical Center), Chaemin Yoon(University of Hong Kong), Yang Wang(First Affiliated Hospital of Guangzhou Medical University), Yue Chai(Chinese University of Hong Kong), Shuofeng Yuan(University of Hong Kong), Tianrenzheng Zhu(University of Hong Kong), Bingjie Hu(Wenzhou Medical University), Huiping Shuai(Chinese University of Hong Kong), Huan Liu(University of Hong Kong), Jasper Fuk‐Woo Chan(Hong Kong Baptist University), Minmin Zhou(University of Hong Kong), Yuxin Hou(University of Hong Kong), Jian Lei(Sichuan University), Yuanchen Liu(University of Hong Kong), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Jialu Shi(University of Hong Kong), Chunfu Xu(National Institute of Biological Sciences, Beijing), Yifei Wang(Southwest Medical University), Guo Zhang(Sichuan University), Honglei Zhang(University of Hong Kong), Yan Chen(PLA Army Service Academy), Qingquan Li(National Institute of Biological Sciences, Beijing), Jingxin Qiao(Sichuan University), Zhen Fang(Shanghai Customs College), Jie Zhou(Chinese University of Hong Kong), Lianzhao Du(University of Hong Kong), Xinyue Deng(Jilin University)
Research Square
November 21, 2024
Cited by 1


Related Papers